Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes - JSON Representation

Raw json | Download

{
  "resourceType" : "Evidence",
  "id" : "236967",
  "meta" : {
    "versionId" : "63",
    "lastUpdated" : "2024-12-14T08:46:28.847Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 236967</b></p><a name=\"236967\"> </a><a name=\"hc236967\"> </a><a name=\"236967-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 63; Last updated: 2024-12-14 08:46:28+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-comparator-only-evidence.html\">ComparatorOnlyEvidence</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Evidence/236967\">https://fevir.net/resources/Evidence/236967</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/236967, outcomeId/313960, picoId/85798, sectionId/73215</p><p><b>name</b>: End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960</p><p><b>title</b>: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ComparatorOnlyEvidence}\">ComparatorOnlyEvidence</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><h3>RelatedArtifacts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style=\"display: none\">*</td><td>Part Of</td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><p><b>note</b>: Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR &gt; 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/).</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Adults with type 2 diabetes -- GLP-1 RA</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"Group-236948.html\">GLP-1 RA Group in Adults with type 2 diabetes</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>End-stage kidney disease</p>\n</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-236965.html\">End-stage kidney disease</a></p></blockquote><p><b>synthesisType</b>: <span title=\"Codes:\">NOTSET</span></p><p><b>studyDesign</b>: <span title=\"Codes:\">NO_STUDY</span></p><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Description</b></td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><div><p>Risk 11.9%</p>\n</div></td><td><span title=\"Codes:{http://terminology.hl7.org/CodeSystem/statistic-type C44256}\">Proportion</span></td><td>0.119</td></tr></table></div>"
  },
  "url" : "https://fevir.net/resources/Evidence/236967",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "urn:ietf:rfc:3986",
      "value" : "https://fevir.net/FOI/236967",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    },
    {
      "type" : {
        "text" : "outcomeId"
      },
      "system" : "https://app.magicapp.org/#/guidelines",
      "value" : "313960"
    },
    {
      "type" : {
        "text" : "picoId"
      },
      "system" : "https://app.magicapp.org/#/guidelines",
      "value" : "85798"
    },
    {
      "type" : {
        "text" : "sectionId"
      },
      "system" : "https://app.magicapp.org/#/guidelines",
      "value" : "73215"
    }
  ],
  "name" : "End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960",
  "title" : "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes",
  "status" : "active",
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "author" : [
    {
      "name" : "Computable Publishing®: MAGIC-to-FEvIR Converter"
    }
  ],
  "useContext" : [
    {
      "code" : {
        "system" : "https://fevir.net/resources/CodeSystem/179423",
        "code" : "evidence-communication",
        "display" : "Evidence Communication"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "ComparatorOnlyEvidence",
            "display" : "ComparatorOnlyEvidence"
          }
        ]
      }
    }
  ],
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "relatedArtifact" : [
    {
      "type" : "part-of",
      "resourceReference" : {
        "type" : "Composition",
        "identifier" : {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "MAGIC-5288-j1Wqrn-conversion-report",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        },
        "display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
      }
    }
  ],
  "description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "note" : [
    {
      "text" : "Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR > 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/)."
    }
  ],
  "variableDefinition" : [
    {
      "description" : "Adults with type 2 diabetes -- GLP-1 RA",
      "variableRole" : "population",
      "observed" : {
        🔗 "reference" : "Group/236948",
        "type" : "Group",
        "identifier" : {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "MAGIC-5288-j1Wqrn-comparator-group-MAGIC-5288-j1Wqrn-comparator-85394-C-85798",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        },
        "display" : "GLP-1 RA Group in Adults with type 2 diabetes"
      }
    },
    {
      "description" : "End-stage kidney disease",
      "variableRole" : "outcome",
      "observed" : {
        🔗 "reference" : "EvidenceVariable/236965",
        "type" : "EvidenceVariable",
        "identifier" : {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "MAGIC-5288-j1Wqrn-313960",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        },
        "display" : "End-stage kidney disease"
      }
    }
  ],
  "synthesisType" : {
    "text" : "NOTSET"
  },
  "studyDesign" : [
    {
      "text" : "NO_STUDY"
    }
  ],
  "statistic" : [
    {
      "description" : "Risk 11.9%",
      "statisticType" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/statistic-type",
            "version" : "5.0.0-cibuild",
            "code" : "C44256",
            "display" : "Proportion"
          }
        ]
      },
      "quantity" : {
        "value" : 0.119
      }
    }
  ]
}